Verse Medical
PrivateLast Round
Series C
Jun 1, 2025
Est. Valuation
$735.18M
Total Funding Raised
$108.15M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Verse Medical operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series C round in June 2025.
Verse Medical is a health technology company that provides an AI-enabled platform to streamline the ordering and coordination of durable medical equipment and home healthcare supplies for health systems, payors, and care teams.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Supply Chain, Medical AI, Workflow Automation
Business Model
B2B2C
Customer Profile
Marketplace Commission, Freemium
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verse Medical Comparables
Compare Verse Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Procurement Partners | 76% | |
| GHX Europe | 73% | |
| Synapse Health | 72% |
For institutional investors. Book with your work email.
Verse Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 1, 2025 | ||||
| Series B | Apr 1, 2024 | ||||
| Series A | Jan 1, 2021 | ||||
| Accelerator | Aug 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Verse Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Webb Investment Network | Series C |
| Hiddentao Ventures | Series B |
| Buckley Ventures | Series C, Series B, Series A |
| General Catalyst | Series C |
| Abstract Ventures | Series B |
| Sapphire Ventures | Series C, Series B |
| Y Combinator | Series C, Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 44% MoM, reaching 80K.
- Jul 22, 2026
Grew 19% QoQ, from 184 to 219 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 19, 2026
On Aug 19th '26 in Ohio, Verse Medical, Inc. partners with Summa Health to deliver more affordable, accessible, and resilient community-based healthcare.
For institutional investors. Book with your work email.
Verse Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Verse Medical's valuation, stock price, and market status.
Is Verse Medical a public or private company?
Verse Medical is a private company.
What is the current stock price of Verse Medical?
Verse Medical is a private company, so its shares have no public market price. Caplight tracks Verse Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Verse Medical worth (valuation)?
Verse Medical's valuation is estimated at $735.2M based on funding round data.
Can I buy Verse Medical stock?
Verse Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Verse Medical's last funding round?
Verse Medical's most recent funding round was Series C on June 1, 2025.
Who are the main investors in Verse Medical?
Key investors in Verse Medical include Y Combinator.
Will Verse Medical IPO soon?
No public IPO plans have been announced for Verse Medical.
How can I track Verse Medical secondary market activity?
Caplight tracks bids, offers, and trades in Verse Medical's shares on secondary markets.